行情

TFX

TFX

泰利福
NYSE

实时行情|Nasdaq Last Sale

281.34
+2.88
+1.03%
盘后: 281.34 0 0.00% 16:11 05/16 EDT
开盘
277.21
昨收
278.46
最高
282.78
最低
276.04
成交量
37.52万
成交额
0
52周最高
428.36
52周最低
256.45
市值
131.95亿
市盈率(TTM)
27.37
分时
5日
1月
3月
1年
5年
3D Systems Announces Establishment of Medical Advisory Board & Appointment of Dr. Stephen K. Klasko as Chair
Dr. Stephen K. Klasko Dr. Stephen K. Klasko ROCK HILL, S.C., May 16, 2022 (GLOBE NEWSWIRE) -- Today, 3D Systems (NYSE:DDD) announced the formation of the company’s first Medical Advisory Board (MAB) and the appointment of Stephen K. Klasko, MD, MBA as Chai...
GlobeNewswire · 11小时前
BRIEF-Teleflex Launches Urolift 2 System, Urolift ATC Advanced Tissue Control System
reuters.com · 3天前
Teleflex launches UroLift 2, UroLift ATC system in US
Teleflex (NYSE:TFX) announced the full U.S. commercial launch of its UroLift 2 system and UroLift ATC system. The company said the UroLift 2 system provides an improved workflow, including a
Seekingalpha · 3天前
Teleflex Highlights Full US Commercial Launch Of UroLift 2 System, UroLift Advanced Tissue Care System
Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today announced the full U.S. commercial launch of its UroLift® 2 System and UroLift ATC® System, and that it will update the
Benzinga · 3天前
Teleflex Announces Full U.S. Commercial Launch of the UroLift® 2 System and UroLift ATC ® Advanced Tissue Control System
Product demonstrations and educational presentations underscore the company’s leadership in advancing care for patients with benign prostatic hyperplasia (BPH)WAYNE, Pa., May 13, 2022 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global ...
GlobeNewswire · 3天前
Benzinga's Top Ratings Upgrades, Downgrades For May 9, 2022
Upgrades
Benzinga · 05/09 14:07
--BofA Securities Initiates Teleflex at Neutral with $315 Price Target
MT Newswires · 05/09 13:13
Looking Into Teleflex's Return On Invested Capital
According to Benzinga Pro, during Q1, Teleflex (NYSE:TFX) earned $77.14 million, a 39.77% increase from the preceding quarter. Teleflex's sales decreased to $641.72 million, a 15.78% change since Q4.
Benzinga · 05/04 14:13
更多
暂无数据
了解TFX最新的财务预测,通过TFX每股收益,每股净资产,每股现金流等数据分析泰利福近期的经营情况,然后做出明智的投资选择。
分析师评级

12位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

8.33%强力推荐
41.67%买入
50.00%中性
0.00%落后大盘
0.00%卖出
目标价格预测
分析师预测TFX价格均价为359.10,最高价位430.00,最低价为295.00。
最高430.00
均价359.10
最低295.00
现价281.34
EPS
实际EPS
预期EPS
0.901.802.703.60
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
机构持股
总机构数: 732
机构持股: 4,930.86万
持股比例: 105.14%
总股本: 4,690.01万
类型机构数股数
增持
166
331.55万
建仓
84
112.08万
减持
189
348.99万
平仓
64
65.03万
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
医疗设备、用品及经销
+0.39%
医疗设备和用品
-0.13%
高管信息
Chairman/President/Chief Executive Officer/Director
Liam Kelly
Chief Financial Officer/Executive Vice President
Thomas Powell
Vice President/General Counsel/Secretary
Daniel Logue
Vice President/Director of Human Resources
Cameron Hicks
Vice President
Jay White
Vice President
James Winters
Lead Director/Independent Director
George Babich
Independent Director
Candace Duncan
Independent Director
Gretchen Haggerty
Independent Director
John Heinmiller
Independent Director
Stephen Klasko
Independent Director
Andrew Krakauer
Independent Director
Stuart Randle
暂无数据
暂无数据
TFX 简况
Teleflex Inc是一家医疗技术产品供应商。该公司主要设计、开发、制造和供应医院和医疗保健提供商使用的用于重症监护和外科应用的常见诊断和治疗程序的一次性医疗设备。该公司通过四个部门运营:美洲;欧洲、中东和非洲(EMEA);亚洲(亚太地区)以及原始设备制造商和开发服务(OEM)。其产品类别包括血管通路、麻醉、介入、外科、介入泌尿外科和泌尿外科。该公司的泌尿专业产品线提供膀胱管理产品。其产品组合包括Foley、间歇性、外部和耻骨上导管等一系列导管;尿液收集器;导管配件以及以“Rusch”品牌销售的手术内泌尿外科产品。

微牛提供Teleflex Incorporated(NYSE-TFX)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的TFX股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易TFX股票基本功能。